(Albany, New York, USA), September 03, 2026 – DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the CAR T-Cell Therapy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates in the CAR T-Cell Therapy Pipeline? @ https://www.delveinsight.com/sample-request/chimeric-antigen-receptor-t-cell-therapy-car-t-pipeline-insight
Key Takeaways from the CAR T-Cell Therapy Pipeline Report
Want to know which companies are leading innovation in CAR T-Cell Therapy? @ CAR T-Cell Therapy Clinical Trials Assessment
The CAR T-Cell Therapy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The CAR T-Cell Therapy Pipeline Report also highlights the unmet needs with respect to the CAR T-Cell Therapy.
CAR T-Cell Therapy Overview
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a transformative personalized immunotherapy that genetically engineers a patient’s T cells to recognize and eliminate cancer cells with high specificity. Despite its remarkable clinical success, particularly in hematological malignancies, CAR-T therapy faces several challenges, including antigen heterogeneity, tumor immune evasion, treatment resistance, limited efficacy in solid tumors, and safety concerns such as cytokine release syndrome (CRS). Ongoing advances in target selection, CAR design, dosing strategies, and combination approaches are aimed at overcoming these limitations and improving therapeutic outcomes. As research continues to evolve, CAR-T therapy is expected to play an increasingly important role in precision oncology, with expanding clinical applications and continued innovation in next-generation CAR-T technologies.
CAR T-Cell Therapy Emerging Drugs Profile
Descartes-08 is an mRNA-modified, autologous CAR T-cell product directed against B-Cell Maturation Antigen (BCMA) that utilizes a novel modality and mechanism of action for treating gMG and other autoimmune diseases. Descartes-08 differs from anti-B-cell agents, which do not address long-lived plasma cells, and differs from FcRn blockers or complement inhibitors, which attempt to intervene only after autoantibodies are produced and pathogenic mediators are amplified. Descartes-08 is intended to halt production of autoantibodies by targeting pathogenic long-lived plasma cells with the potential to survive for decades within the body. Currently, the drug is in the Phase III stage of its development for the treatment of Myasthenia gravis (gMG).
Zola-cel (zolacabtagene autoleucel) is an investigational autologous CD19-directed CAR-T cell therapy being developed by Bristol Myers Squibb for the treatment of severe autoimmune diseases rather than cancer. It is designed to selectively eliminate CD19-positive B cells, which are key drivers of autoantibody production, with the goal of achieving an “immune reset” after a single infusion. Early clinical studies have demonstrated encouraging efficacy and a manageable safety profile, with durable disease control observed in patients with refractory autoimmune disorders. Bristol Myers Squibb is currently evaluating zola-cel across multiple indications, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), multiple sclerosis (MS), myasthenia gravis (MG), and idiopathic inflammatory myopathies (IIM). Currently the drug is in Phase III stage of its development for the treatment of Systemic scleroderma.
CABA-201 is an investigational autologous CD19-directed CAR-T cell therapy developed by Cabaletta Bio for the treatment of B cell-mediated autoimmune diseases. The therapy incorporates a fully human CD19-binding domain and a 4-1BB co-stimulatory domain, enabling deep but transient depletion of CD19-positive B cells following a single infusion. This approach is designed to achieve an “immune system reset,” with the goal of inducing durable, drug-free remission without the need for chronic immunosuppressive therapy. CABA-201 is currently being evaluated in the RESET™ clinical development program across multiple autoimmune indications, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathies (myositis), generalized myasthenia gravis (gMG), and pemphigus vulgaris (PV). Early clinical data have demonstrated encouraging B-cell depletion, initial signs of clinical efficacy, and a manageable safety profile, supporting its potential as a disease-modifying, one-time cellular therapy for autoimmune disorders. Currently the drug is in Phase II/III stage of its development for the treatment of Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy.
FT819 is an investigational off-the-shelf, induced pluripotent stem cell (iPSC)-derived CD19-targeted CAR-T cell therapy developed by Fate Therapeutics for the treatment of B cell-mediated autoimmune diseases. Unlike conventional autologous CAR-T therapies, FT819 is manufactured from a clonal iPSC master cell bank, enabling standardized, readily available treatment without the need for patient-specific cell manufacturing. The therapy incorporates a 1XX CAR targeting CD19, which is designed to provide potent and sustained B-cell depletion while improving safety and T-cell persistence. FT819 is currently being evaluated in clinical trials for systemic lupus erythematosus (SLE), lupus nephritis (LN), systemic sclerosis (SSc), ANCA-associated vasculitis (AAV), and idiopathic inflammatory myopathies (IIM). Early clinical data have demonstrated encouraging efficacy, effective B-cell depletion, and a favorable safety profile, supporting its potential as a scalable next-generation CAR-T therapy for autoimmune diseases. But currently the therapy is in Phase II which is the highest stage of its development for the treatment of systemic lupus erythematosus and lupus nephritis.
ALLO-501A is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy developed by Allogene Therapeutics for the treatment of relapsed or refractory large B-cell lymphoma (LBCL). Clinical studies have demonstrated encouraging efficacy, durable responses, and a manageable safety profile, supporting its potential as a readily available alternative to autologous CAR-T therapies. Currently, the drug is in Phase II stage of its development for the treatment of Diffuse large B cell lymphoma.
CTX112 is an investigational allogeneic, off-the-shelf CD19-targeted CAR-T cell therapy developed by CRISPR Therapeutics for the treatment of B-cell malignancies. Manufactured from healthy donor T cells using CRISPR/Cas9 gene-editing technology, CTX112 is designed to enhance persistence, improve antitumor activity, and reduce the risk of graft-versus-host disease. The therapy is currently being evaluated in clinical trials for relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early data demonstrating encouraging clinical activity and a manageable safety profile. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsed/Refractory Hematologic Autoimmune Disease.
CT1190B is an investigational autologous CD19-targeted CAR-T cell therapy developed by CARsgen Therapeutics for the treatment of B-cell malignancies, particularly relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The therapy is engineered to selectively eliminate CD19-positive malignant B cells, with the goal of achieving durable clinical responses. Early clinical studies have demonstrated promising antitumor activity and a manageable safety profile, supporting its continued clinical development as a treatment option for patients with relapsed or refractory B-cell cancers. Currently, the drug is in Phase I stage of its development for the treatment of Systemic Lupus Erythematosus (SLE).
AUTO8 is an investigational dual-targeted autologous CAR-T cell therapy developed by Autolus Therapeutics for the treatment of relapsed or refractory multiple myeloma. The therapy combines an optimized BCMA-targeting CAR with Autolus’ fast off-rate CD19 CAR (obe-cel) to enhance tumor cell killing, improve treatment durability, and reduce antigen escape. AUTO8 is currently being evaluated in a Phase I clinical trial, with early results demonstrating encouraging clinical activity, durable responses, and a favorable safety profile.
If you’re tracking ongoing CAR T-Cell Therapy Clinical trials @ CAR T-Cell Therapy Treatment Drugs
The CAR T-Cell Therapy Pipeline report provides insights into:-
CAR T-Cell Therapy Companies
Caribou Biosciences, Allogene Therapeutics, Synthekine, Shanghai Simnova Biotechnology, Sana Biotechnology, Zhejiang University, Janssen Research & Development, Beijing Immunochina Medical Science & Technology, M.D. Anderson Cancer Center, SecuraBio, CARsgen Therapeutics, Caribou Biosciences, Atara Bio therapeutics, Wugen, Vor Biopharma, Juventas Cell Therapy, Hebei Senlang Biotechnology, Cellular Biomedicine Group, Oncternal Therapeutics, Autolus Limited, Lyell Immunopharma, Gracell Biopharmaceuticals and others.
CAR T-Cell Therapy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
CAR T-Cell Therapy Products have been categorized under various Molecule types such as,
From emerging drug candidates to competitive intelligence, the CAR T-Cell Therapy Pipeline Report @ CAR T-Cell Therapy Market Drivers and Barriers, and Future Perspectives
Scope of the CAR T-Cell Therapy Pipeline Report
Discover what’s next for the CAR T-Cell Therapy Treatment landscape in this detailed analysis @ CAR T-Cell Therapy Emerging Drugs and Major Players
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/car-t-pipeline-insight
